A company with extensive experience of generic pharmaceuticals
A company with extensive experience of generic pharmaceuticals, Medis offers a broad portfolio of products and intellectual property to other pharmaceutical companies. We have a proven track record in securing regulatory approval prior to patent expiries, and have obtained marketing authorisations in over 140 countries to date.
Medis draws on the development and manufacturing capabilities of its parent company, Teva Pharmaceuticals Ltd. (NYSE and TASE:TEVA), whose R&D specialists maintain a strong development pipeline.
Generic pharmaceutical products for human use
We provide generic pharmaceutical products for human use, mainly in the form of tablets, capsules and injections. Our comprehensive portfolio includes a growing range of specialist oncology products and product formulations include modified release, solid oral dosage, semi-solids, suspensions, transdermals, suppositories, creams, ointments, liquids and injectables.
Medis has local presence in Iceland, Germany, France, Spain, Italy, Poland, Russia, Singapore, Brazil, and Australia, and numerous regional managers and business development support elsewhere. We provide services and products to most European nations and we have marketing authorizations in fast expanding markets such as Russia, Poland, South America and Asia.